Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Climb Bio, Inc. stock logo
CLYM
Climb Bio
$2.23
-3.0%
$1.63
$1.05
$8.79
$151.11M-0.05886,105 shs288,883 shs
Organogenesis stock logo
ORGO
Organogenesis
$5.15
+0.6%
$4.50
$2.45
$6.71
$653.32M1.75651,073 shs314,198 shs
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
$3.59
-2.7%
$3.54
$1.77
$10.72
$618.96M1.61.46 million shs1.09 million shs
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
$23.40
+1.6%
$20.09
$11.56
$29.79
$601.20M2.04144,607 shs130,322 shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Climb Bio, Inc. stock logo
CLYM
Climb Bio
0.00%-6.30%+53.79%+88.98%+222,999,900.00%
Organogenesis stock logo
ORGO
Organogenesis
0.00%+5.32%+14.19%+93.61%+78.82%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
0.00%-2.71%+6.85%+12.89%-47.13%
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
0.00%+0.39%+7.54%+36.76%+38.87%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Climb Bio, Inc. stock logo
CLYM
Climb Bio
3.3058 of 5 stars
3.70.00.00.03.32.51.3
Organogenesis stock logo
ORGO
Organogenesis
4.3044 of 5 stars
3.31.00.04.33.54.20.6
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
2.0271 of 5 stars
3.50.00.00.02.72.50.6
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
2.3981 of 5 stars
3.52.00.00.03.02.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Climb Bio, Inc. stock logo
CLYM
Climb Bio
3.33
Buy$9.00303.59% Upside
Organogenesis stock logo
ORGO
Organogenesis
2.67
Moderate Buy$7.5045.63% Upside
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
2.92
Moderate Buy$17.08375.86% Upside
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
3.00
Buy$50.14114.29% Upside

Current Analyst Ratings Breakdown

Latest CLYM, RLAY, ORGO, and TRML Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/26/2025
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $14.00
8/15/2025
Climb Bio, Inc. stock logo
CLYM
Climb Bio
Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
8/15/2025
Climb Bio, Inc. stock logo
CLYM
Climb Bio
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$9.00
8/14/2025
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$70.00
8/14/2025
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$55.00
8/8/2025
Organogenesis stock logo
ORGO
Organogenesis
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$7.00 ➝ $9.00
8/8/2025
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetStrong-Buy ➝ Strong-Buy$29.00 ➝ $19.00
7/15/2025
Organogenesis stock logo
ORGO
Organogenesis
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
7/15/2025
Organogenesis stock logo
ORGO
Organogenesis
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$7.00
6/6/2025
Climb Bio, Inc. stock logo
CLYM
Climb Bio
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$10.00
(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Climb Bio, Inc. stock logo
CLYM
Climb Bio
N/AN/AN/AN/A$3.15 per shareN/A
Organogenesis stock logo
ORGO
Organogenesis
$482.04M1.36$0.21 per share24.68$2.09 per share2.46
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
$10.01M61.83N/AN/A$4.65 per share0.77
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
N/AN/AN/AN/A$11.71 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Climb Bio, Inc. stock logo
CLYM
Climb Bio
-$73.90M-$0.70N/AN/AN/AN/A-23.10%-22.47%11/11/2025 (Estimated)
Organogenesis stock logo
ORGO
Organogenesis
$860K-$0.14N/AN/AN/A-1.92%-0.37%-0.20%11/11/2025 (Estimated)
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
-$337.71M-$1.95N/AN/AN/AN/A-41.49%-37.43%11/5/2025 (Estimated)
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
-$73.21M-$3.43N/AN/AN/AN/A-30.50%-29.63%11/6/2025 (Estimated)

Latest CLYM, RLAY, ORGO, and TRML Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
-$0.94-$0.90+$0.04-$0.90N/AN/A
8/12/2025Q2 2025
Climb Bio, Inc. stock logo
CLYM
Climb Bio
-$0.19-$0.13+$0.06-$0.13N/AN/A
8/7/2025Q2 2025
Organogenesis stock logo
ORGO
Organogenesis
-$0.01-$0.09-$0.08-$0.10$104.75 million$101.01 million
8/7/2025Q2 2025
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
-$0.49-$0.41+$0.08-$0.41$0.07 million$0.70 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Climb Bio, Inc. stock logo
CLYM
Climb Bio
N/AN/AN/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
N/AN/AN/AN/AN/A
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Climb Bio, Inc. stock logo
CLYM
Climb Bio
N/A
14.08
14.08
Organogenesis stock logo
ORGO
Organogenesis
N/A
3.95
3.45
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
N/A
20.92
20.92
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
N/A
24.68
24.68

Institutional Ownership

CompanyInstitutional Ownership
Climb Bio, Inc. stock logo
CLYM
Climb Bio
69.76%
Organogenesis stock logo
ORGO
Organogenesis
49.57%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
96.98%
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
91.89%

Insider Ownership

CompanyInsider Ownership
Climb Bio, Inc. stock logo
CLYM
Climb Bio
3.20%
Organogenesis stock logo
ORGO
Organogenesis
33.00%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
4.32%
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
13.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Climb Bio, Inc. stock logo
CLYM
Climb Bio
967.76 million65.60 millionN/A
Organogenesis stock logo
ORGO
Organogenesis
950126.86 million85.00 millionOptionable
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
330172.41 million164.96 millionOptionable
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
4425.69 million22.35 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Climb Bio stock logo

Climb Bio NASDAQ:CLYM

$2.23 -0.07 (-3.04%)
As of 08/29/2025 04:00 PM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$5.15 +0.03 (+0.59%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$5.14 -0.01 (-0.10%)
As of 08/29/2025 06:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Relay Therapeutics stock logo

Relay Therapeutics NASDAQ:RLAY

$3.59 -0.10 (-2.71%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$3.58 0.00 (-0.14%)
As of 08/29/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Tourmaline Bio stock logo

Tourmaline Bio NASDAQ:TRML

$23.40 +0.37 (+1.61%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$23.50 +0.10 (+0.43%)
As of 08/29/2025 06:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.